Sequence Homology Within the Morbilliviruses

SHMUEL ROZENBLATT,^{1,2*} ORLY EIZENBERG,¹ RACHEL BEN-LEVY,¹ VERED LAVIE,¹ and WILLIAM J. BELLINI²

Department of Virology, Weizmann Institute of Science, Rehovot, Israel,¹ and Laboratory of Molecular Genetics, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Maryland 20205²

Received 27 June 1984/Accepted 25 October 1984

Double-stranded cDNA synthesized from total polyadenylate-containing mRNA extracted from monkey kidney cells infected with canine distemper virus (CDV) was cloned into the *PstI* site of *Escherichia coli* plasmid pBR322. Clones containing CDV DNA were identified by hybridization to a CDV-specific ³²P-labeled cDNA. A cDNA clone containing an insert 1,700 base pairs (CDV 364) has been identified as the reverse transcript of the mRNA coding for the nucleocapsid protein. The size of the mRNA species complementary to this insert is 1,850 nucleotides, as determined by the Northern technique. Hybridization experiments and heteroduplex mapping indicated homology between the central region of the CDV and measles virus nucleocapsid gene. The completion of the nucleotide sequence analysis of the measles virus gene allowed the reconstruction of the entire coding region of the measles virus gene and a comparison with the counterpart sequence of CDV. This comparison delineated three regions: (i) a region of high homology (nucleotides 501 to 1215), in which 77% of the nucleotides and 88% of the encoded amino acids are identical; (ii) a region of moderate homology at the 5' end of the message (nucleotides 1 to 500), in which 59% of the nucleotides and 66% of the encoded amino acids are identical; (iii) a region of little or no homology (nucleotides 1216 to 1625) near the 3' end of the message.

Canine distemper virus (CDV) and measles virus (MV) are members of the morbillivirus subgroup of paramyxoviruses. Strong immunological cross-reactivity has been observed among all polypeptides of these viruses, with the possible exception of the hemagglutinin (12, 15, 17, 25). Both viruses can establish persistent infection in cell culture (21, 26), and both can invade the central nervous system of their natural host. A slowly progressing neurological disease known as subacute sclerosing panencephalitis has been directly correlated with the presence of measles virus in the central nervous system of human patients (8, 11, 14, 18). Similarly, CDV has been shown to be the causative agent in a slow neurological disease, old dog encephalitis (1, 9, 23). Both viruses have been implicated as being involved in multiple sclerosis, but the evidence for this has been weak at best.

We have undertaken a comparative study of these two morbilliviruses as an approach to the elucidation of possible molecular events that could lead to the alteration of these viruses from an acute infection to one producing a "slow" virus syndrome. In the initial phase of this work, we have previously cloned three of the MV genes (4, 5, 11, 19). In the present study, we have identified cDNA clones of CDV. One of these clones, containing almost the entire coding region of the CDV nucleocapsid gene, and a measles clone encompassing this same coding region have been completely sequenced and analyzed with respect to nucleotide and amino acid sequence homologies.

MATERIALS AND METHODS

Cells and viruses. The Onderstepöort strain of CDV was obtained from M. Appel (Cornell University, Ithaca, N.Y.) and was plaque purified twice in the CV-1 line of African green monkey kidney cells. A stock was prepared by infecting CV-1 cells at a multiplicity of infection of 1/1,000. After the development of a marked cytopathic effect, virus was harvested (20).

Preparation of RNA. CV-1 cells (3×10^8) were infected with plaque-purified CDV at 0.5 PFU per cell; 18 h later, cytoplasmic RNA was extracted. RNAs were purified by successive phenol-chloroform-isoamyl alcohol extraction followed by LiCl precipitation. Polyadenylated [poly(A)⁺] mRNAs were then purified by oligodeoxythymidylate-cellulose chromatography (2).

cDNA libraries. The cDNA library of canine distemper virus was constructed by oligodeoxythymidylate priming of CDV mRNA. Methods employed for first- and second-strand synthesis, tailing, and insertion into pBR322 at the *PstI* site have been described previously (11). The constructions of the cDNA library produced by reverse transcription of measles mRNA and the genomic library have been previously described (5, 11).

Detection of CDV-specific clones. Transformants were transferred onto nitrocellulose filters and hybridized with ³²P-labeled cDNA probes (2×10^5 cpm/ml) prepared from poly(A)⁺ RNA from CDV acutely infected cells. The probe was incubated before hybridization with a 100-fold excess (10 µg) of poly(A)⁺ RNA from uninfected cells (19, 20). The incubation was performed at 68°C for 4 h in a 100-µl reaction mixture containing 0.27 M sodium citrate (pH 7.2), 0.9 M NaCl, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, and 150 µg of sonicated salmon sperm DNA. After hybridization, filters were washed and autoradiographed.

Northern blot hybridization. Poly(A)⁺ RNA (1 to 2 μ g) was electrophoretically separated in formaldehyde-agarose (1%) gels by the method of Derman et al. (10). The RNA was transblotted onto Zeta probe membrane filters (Bio-Rad Laboratories) which were then baked for 2 h. Hybridization to nick-translated CDV 364 (5 × 10⁷ dpm/ μ g) was performed at 42°C in 50% formamide (stringent conditions) or in 35% formamide (decreased stringency) for 12 to 15 h. Hybridization solutions, in addition to the formamide, contained 5× SSPE (0.90 M NaCl, 50 mM sodium phosphate [pH 7.0], 5 mM EDTA), 0.02% (wt/vol) bovine serum albumin, Ficoll 400, polyvinylpyrrolidone, 0.3% sodium dodecyl sulfate (SDS), and 100 μ g of sonicated salmon sperm DNA per ml.

^{*} Corresponding author.




FIG. 1. Sizing of CDV DNA clone. (Top) Plasmid DNAs, digested with *PstI*, were electrophoresed on a 1.5% agarose slab gel. Lanes: A, pBR322; B, CDV 364. Simian virus 40 DNAs digested with *Hin*fI were used as markers. (Bottom) Heteroduplex of clone CDV 364 and pBR322 linearized with *Eco*RI, denatured, and annealed. Inset shows interpretive drawing.

After hybridization, the filters were washed at 45°C with $2 \times$ SSPE containing 0.2% SDS (three times for 20 min each). For stringent washing, the final wash was performed at 60°C with 0.2× SSPE containing 0.2% SDS for 30 min. For decreased stringency, the final wash was done at 50°C with 1× SSPE containing 0.2% SDS for 30 min. Filters were exposed to Kodak XR-2 X-ray film with the use of a screen and stored at -70° C until developed.

RESULTS

Construction and identification of cDNA clones. The population of double-stranded cDNA prepared from $poly(A)^+$ RNA extracted from CDV-infected cells was tailed with oligodeoxycytidylate and inserted into appropriately tailed pBR322 at the *PstI* site. The circularized hybrid DNA was introduced into Ca²⁺-sensitized *Escherichia coli* HB101.

Transformants (4,000 clones) resistant to tetracycline (15 μ g/ml) were isolated, and 384 clones containing CDV sequences were identified by a selective hybridization method adapted for screening clones that contain CDV-DNA sequences (11). Characterization of one clone, clone 364, revealed an insert of ca. 1,700 base pairs (bp). The size and nature of the cDNA insert were characterized by two methods. Digestion of CDV 364 DNA with *PstI* (Fig. 1, lane B) generated three fragments. One corresponded in size to linear pBR322 DNA, a second fragment consisted of 1,100

bp, and a third fragment was 600 bp. The size of the inserted fragment was further confirmed by electron microscopic studies. The lower part of Fig. 1 shows an electron micrograph of heteroduplex molecules formed by reassociation of pBR322 and CDV 364 DNAs that were linearized by digestion with *Eco*RI which does not cut the insert. The length of the inserted CDV sequence appeared to be $1,750 \pm 50$ bp, in good agreement with the length determined by agarose gel electrophoresis.

Hybridization of clone CDV 364 with CDV and MV mRNA. For a determination of the size of the CDV mRNA complementary to CDV 364 and an assessment of the relatedness between this clone and MV mRNA, Northern blot analyses were performed. For these studies, mRNA extracted from cells acutely infected with CDV or MV was fractionated on agarose gels under denaturing conditions together with ¹⁴Clabeled rRNA markers. Subsequently, the RNA was electroblotted onto Zeta probe membrane. Clone CDV 364 plasmid DNA was nick translated in vitro and used as a hybridization probe, under both stringent conditions and decreased stringency, using duplicate blots. Under stringent conditions of hybridization, CDV 364 DNA hybridized only to mRNA extracted from CDV-infected cells, not to mRNA extracted from MV-infected cells (Fig. 2A). A strong hybrid-




FIG. 2. Northern blot analysis of $poly(A)^+$ RNA from CDV- and MV-infected cells, with CDV 364 as probe. $Poly(A)^+$ RNA from cells infected with CDV (lanes 1) or MV (lanes 3) was fractionated under denaturing conditions (10) in 1% agarose gels. rRNA (¹⁴C-labeled) was used as a size marker (lanes 2). After being transblotted onto Zeta probe, duplicate membranes were hybridized with CDV 364 plasmid ³²P-labeled DNA under (A) stringent conditions or (B) decreased stringency, as detailed in the text.




FIG. 3. Electron microscopy of heteroduplex DNAs. pBR322 and three cloned DNAs (CDV 364), measles 15, and measles 16 (1 μ g of each) were linearized with *Eco*RI, denatured, and annealed (7). (a) pBR322 and CDV 364; (b) MV CL-16 and CDV 364; (c) MV CL-15 and CDV 364. Insets (surrounded by white) show interpretive drawings.


ization signal was observed with an mRNA species of ca. 1,850 bases, whereas a weak signal was observed with an mRNA of ca. 3,500 bases. Under decreased stringency, a strong hybridization signal was again seen with the CDV mRNA, as well as a clear hybridization signal with the measles mRNA (Fig. 2B). The signals obtained were with mRNA species similar in size to those observed under high stringency of hybridization with CDV mRNA, i.e., ca. 1,850 bases, and more weakly with the mRNA of 3,500 bases. Recently, Barrett and Mahy have reported the identification of a CDV cDNA clone specific for the nucleocapsid gene (3). This clone hybridized to an mRNA of essentially identical size as detected by CDV 364. Moreover, we have reported a nucleocapsid clone of MV (MV CL-15) that detects a measles-specified mRNA of 1,800 bases (11).

Heteroduplexes of CDV 364 and MV CL-15. The possibility that CDV 364 might contain sequence homology with MV CL-15 was explored by using heteroduplex formation and electron microscopic examination. The pBR plasmid DNA containing CDV 364 insert was linearized with *Eco*RI and annealed with *Eco*RI-linearized plasmid MV CL-15 DNA or MV CL-16. The latter MV clones contain the identical 1,400-bp insert of the MV nucleocapsid clone inserted in pBR322 DNA at the *PstI* site, but in opposite orientation.

Figure 3 shows electron micrographs of heteroduplex molecules formed by reassociation of CDV 364 with MV CL-16 (Fig. 3b) and MV CL-15 (Fig. 3c). A double-stranded region within the insert location was observed only when CDV 364 was annealed with MV CL-15. The length of the double-stranded region was determined to be 681 ± 48 bp based on the statistical analysis of 11 molecules. These results clearly demonstrated a sequence similarity between the MV nucleocapsid clone and a region of CDV 364 and strongly suggested that CDV 364 is a nucleocapsid clone.

Nucleotide sequence of CDV and MV nucleocapsid. Confirmation of the nucleotide homology between CDV 364 and MV CL-15 was established by nucleotide sequencing, done by both the chemical method (16) and the chain termination method (22). The CDV 364- and MV CL-15-related clones employed for establishing the nucleotide sequence are schematically illustrated in Fig. 4. Clones CDV 360 and CDV 93 were selected from the CDV message library, with end-labeled CDV 364 as probe. Clone MV_0 -3 was obtained from Martin Billeter (University of Zürich, Zürich, Switzerland). This 605-bp clone was derived from the precise 3'-proximal end of the MV genome, and the nucleotide sequence has been previously reported (6). The last 208 nucleotides of MV_{0} -3 are identical to the first 208 nucleotides of MV CL-15. Clone pWB 9D8 was selected from a measles genomic library and contains the last 207 nucleotides present within MV CL-15 before crossing the intercistronic boundary into the next downstream gene, the phosphoprotein (4). All CDV and MV clones described were completely sequenced.

The combined sequences obtained from the MV clones permitted the reconstruction of the entire coding sequence for measles nucleocapsid. This nucleotide sequence, begin-








FIG. 4. Schematic representation of the cDNA clones employed in sequencing of (A) CDV and (B) MV nucleocapsid. *, MV_0 -3 was received from M. Billeter (5).

15 45 ATGGCCACAC TITTAAGGAG CITAGCATTG TICAAAAGAA ACAAGGACAA ACCACCCATT ACATCAGGAT CCGGTGGAGC CATCAGAGGA - ndC++ +++++G++G+ CTCG++++C+ +++C++TC++ G+C++T++C+ ++++G+++++ ATCA++++++ 120 135 150 ATCAAACACA TTATTATAGT ACCAATCCCT GGAGATTCCT CAATTACCAC TCGATCCAGA CTTCTGGACC GGTTGGTCAG GTTAATTGGA **A**G**TG *C******* C*T*****G **T****AA GC***GTT** AA****TC** **AT****TA *AC*T**T** ***GG****T 210 AACCCGGATG TGAGCGGGCC CAAACTAACA GGGGCACTAA TAGGTATATT ATCCTTATTT GTGGAGTCTC CAGGTCAATT GATTCAGAGG . 300 330 295 315 ATCACCGATG ACCCTGACGT TAGCATAAGG CTGTTAGAGG TTGTCCAGAG TGACCAGTCA CAATCTGGCC TTACCTTCGC ATCAAGAGGT ****TA**C* ******T** A*****C*A* T*AG***** *AA*A*CA** CAT*A*C**T GCT*GC**T* ****A**T** ***C****A 135 200 ACCAACATGG AGGATGAGGC GGACCAATAC TITICACATG ATGATCCAAT TAGTAGTGAT CAATCCAGGT TCGGATGGTT CGAGAACAAG G+A+G+TG+A TTCTGAG+++ A++TG+G+T+ ++CAA+AT++ TA++CGA+GG GTCG+AA+C+ +++GGGCAA+ +A++C++++ A++++T+++ 510 525 GAAATCTCAG ATATTGAAGT GCAAGACCCT GAGGGATTCA ACATGATTCT GGGTACCATC CTAGCCCAAA TTTGGGTCTT GCTCGCAAAG **T**AGT** *C**A***** TG*TA*TG** ***CA**** *T**AT*G** A*C*T**** T*G**T**** ****A**C* ***A**T**A 570 585 600 615 GCGGTTACGG CCCCAGACAC GGCAGCTGAT TCGGAGCTAA GAAGGTGGAT AAAGTACACC CAACAAAGAA GGGTAGTTGG TGAATTTAGA 660 675 690 720 TIGGAGAGAA AATGGTTGGA TGTGGTGAGG AACATTATTG CCGAGGACCT CTCCTTACGC CGATTCATGG TCGCTCTAAT CCTGGATATC A**A*C*A** TC***C*T** *A*T**T**A ****GG**** *T******* A**T**GA*G ********* *G**G**C** *T****C*** 735 750 765 780 795 810 AAGAGAACAC CCGGAAACAA ACCCAGGATT GCTGAAATGA TATGTGACAT TGATACATAT ATCGTAGAGG CAGGATTAGC CAGTTTTATC **AC**T*C* *A******** G**T**A*** ********* *T******** A****AC**C **T**G**A* *T**G**** T*****C*** 840 855 825 870 900 CTGACTATTA AGTITGGGAT AGAAACTATG TATCCTGCTC TTGGACTGCA TGAATTTGCT GGTGAGTTAT CCACACTTGA GTCCTTGATG **A*****C* ******C** T********* *****G**** ****GT**** ***GT***T*C **A**A***A *A**TA**** A***C*C*C*** 960 975 945 AACCTTTACC AGCAAATGGG GAAACCTGCA CCCTACATGG TAAACCTGGA GAACTCAATT CAGAACAAGT TCAGTGCAGG ATCATACCCT *TG**A**T* *A**G***** TG**A*A*** **G****** *T*T*T**** A*****TG** **A****A* *T******* G**C*****A 1065 1035 1050 1005 1020 1125 1155 1110 1140 TATTITAGAT TAGGGCAAGA GATGGTAAGG AGGTCAGCTG GAAAGGTCAG TTCCACATTA GCATCTGAAC TCGGTATCAC TGCCGAGGAT **C**C**C* *C******* A****T*** **A**T**C* *C**A**A** C**TG**C*T **CG*C*T *T**C***** CAAG*****A 1200 1195 1215 GCAAGGCTTG TTTCAGAGAT TGCAATGCAT ACTACTGAGG ACAAGATCAG TAGAGCGGTT GGACCCAGAC AAGCCCAAGT ATCATTTCTA **TCA***A* *G*****A** A***TCCA*G **A**A**** **CG**CA*T *C****TAC* **T**T*AG* **T****A* CA*T****G 1290 1275 1305 1320 1335 CAGGGTGATC AAAGTGAGAA TGAGCTACCG CGATTGGGGG GCAAGGAAGA TAGGAGGGTC AAACAGAGTC GAGGAGAAGC CAGGGAGAGAG **CTCG+*AA G*TCC+*AGT C+CCAAT*AA *A*CCCCCCAA C+*TCA*CA* G***TCC+AA **C***G*AG ***ACA**TA *CCCATTCA* 1395 1410 1425 TACAGAGAAA CCGGGCCCAG CAGAGCAAGT GATGCGAGAG CTGCCCATCT TCCAACCGGC ACACCCCTAG ACATTGACAC TGCATCGAG *T***T**CG AAA***TTCT AG*GTAT*CC CCA*ATGTCA ACAGTTC*GA A*GG*GT**G T***G*TAT* ***CCC*A*T **TCCAA**T 1455 1470 1485 1500 1515 TCCAGCCAAG ATCCGCAGGA CAGTCGAAGG TCAGCTGAGC CCCTGCTTAG CTGCAAGCCA TGGCAGGAAT CTCGGAAGAA CAAGGCTCAG GATG#AA#T# #CGATG#TCG G#AATCG#T# GA###AATCG ##AA#A#G## GATGCTTA#T AA#AT#CTCA G##AACCTGG G#CCAG#G#A 1560 1575 1590 1620 ACACGGACAC CCCTACAGTG TACAATGACA GAAATCTTCT AGACTAGGTG CGAGAGGCCG AGGGCCAGAA CAACATCCGC CTACCCTCCA GATAATT+T+ +TG+TT+TAA +GAC+AAGAG CT+C++AAT+ +A+TATTCAA GACC++T+TT GCAT+AGTC+ AC+AT+ATCA T+CTAAA+TC TCATTGTTAT A (n) ATTA + A(n)

FIG. 5. Nucleotide sequences of MV (top line) and CDV (bottom line) nucleocapsids. The sequences are displayed as (+) genome sense and represent the putative coding regions. Asterisks represent nucleotide identity; nd, sequence not determined.

ning at the putative initiation codon, is shown in Fig. 5 (top line). This sequence begins 109 nucleotides from the precise 3'-OH end of the measles genome and is written as (+)genome sense. The bases specify 523 amino acids (Fig. 6, top line) in a contiguous reading frame which terminates 61 nucleotides from the poly(A)⁺ tail. The calculated molecular weight of the MV nucleocapsid protein is 58,111. This figure is in close agreement with the estimated molecular weight determined by SDS-polyacrylamide gel electrophoresis, i.e., 60,000 (20).

The largest CDV nucleocapsid clone (364) and CDV 360 both appear to be derived from the faithful reverse transcription of CDV-N mRNA beginning within the $poly(A)^+$ tail. This is supported by the presence of 41 adenosine residues at

the 3' end (+) sense of CDV 364, whereas the oligodeoxythymidylate primer contained only 12 to 18 deoxythymidylate residues. Unfortunately, neither clone 364 nor any other clone thus far examined extended far enough toward the 5' end of the CDV-N message to allow the determination of the entire coding region of CDV nucleocapsid. Clone 364 contains 1,598 bp of the CDV nucleocapsid. A single open reading frame was found that encodes 514 amino acids and terminates 56 nucleotides from the poly(A)⁺ tail (Fig. 5 and 6, bottom lines). We chose to align the sequences for purposes of the homology comparison at the first termination codon of each sequence (positions 1570 to 1572). This alignment clearly demonstrated a great deal of homology between the two sequences, at both the nucleotide and

MET	Ala	Thr	Leu	15 Leu	Arg	Ser	Leu	Ala - nd	30 Leu *	Phe *	Lys *	Arg •	Asn Thr	45 Lys Arg	Asp *	Lys Gin	Pro t	Pro •	60 lle Leu	Thr Ala	Ser •	Gly	Ser •	75 Gly	Gly	Ala •	lie Ser	Arg *	90 Giy
lie *	Lys *	His •	lle Val	105 Ile *	lle *	Vai *	Pro Leu	lle *	120 Pro	Giy	Asp *	Ser *	Ser *	135 Ile *	Thr Val	Thr *	Arg *	Ser *	150 Arg	Leu *	Leu •	Asp *	Arg *	165 Leu *	Va: •	Arg *	Leu *	lle Vai	180 Giy
Asn Asp	Pro *	Asp Lys	Vai Ile	19 5 Ser Asn	Gly	Pro *	Lys *	Leu *	210 Thr *	Giy	Ala lle	Leu *	lie *	225 Gly Ser	lie *	Leu *	Ser *	Leu *	240 Phe	Va! *	Giu *	Ser *	Pro +	255 Giy	Gin *	Leu *	lle *	Gin t	270 Arg *
ile *	Thr lie	Asp *	Asp *	285 Pro *	Asp t	Val *	Ser •	lle *	300 Arg Lys	Leu *	Leu Val	Glu •	Vai *	315 Val lie	Gin Pro	Ser *		Gin Asn	330 Ser *	Gin Ala	Ser Cys	Gly	Leu *	345 Thr *	Phe *	Ala *	Ser *	Arg *	360 Gly ★
_				375					390					405					420					435					450
Thr Ala	Asn Ser	MET Trp	Giu lie	Asp Leu	Giu Arg	Ala *	Asp *	GIn Glu	Tyr Phe	Phe •	Ser Lys	His Ile	Asp Val	Asp *	Pro Giu	lle Gly	Ser *	Ser Lys	Asp Ala	GIn *	Ser Gly	Arg Gin		Giy *	Trp •	Phe Leu	Glu *	Asn •	Lys *
<u>.</u>				465	A .				480					49 5				_	510					525					540
Glu Asp	lle •	Ser Val	Asp *	lle *	Giu *	Val *	Gin Asp	Asp Asn	Pro Ala	Glu •	Gly Gin	Phe *	Asn *	Met Ile	lle Leu	Leu *	Gly Ala	Thr Ser	ile *	Leu *	Aia *	Gin *	łle +	Trp *	Vai lie	Leu *	Leu *	Aia *	Lys *
	M-1	.		555		-	•		570					585					600					615					630
Ala *	Va:	Thr •	Ala *	Pro *	Asp *	Thr +	Ala +	Ala *	Asp •	Ser *	Giu •	Leu Met	Arg •	Arg t	Trp +	lle *	Lys •	Tyr +	Thr +	Gin *	Gir *	Arg •	Arg •	Vai *	Val *	Gly •	Glu *	Phe *	Arg •
	<u>_</u>			645					660					675					690					705					720
Leu Met	Glu Asn		Lys He	Trp *	Leu *	Asp *	Vai 1ie	Va:	Arç *	Asn *	lie Arg	ile •	Ala •	Giu *	Asp *	Leu *	Ser *	Leu *	Arg *	Arg t	Phe *	Met *	Val •	Ala *	Leu *	11e *	Leu *	Asp *	11e •
		_		735			_		750					765					780					795					810
Lys *	Arg *	Thr Ser	Pro *	Giy *	Asr *	Lys *	Pro *	Arg *	lle *	Ala *	Giu *	Met	lie *	Cys *	Asp *	lle *	Asp *	Thr Asn	Tyr •	lie *	Vai •	Giu *	Ala *	Giy *	Leu •	Ala *	Ser *	Phe *	!!e *
				825				_	840	_	_			855				_	870					885					900
Leu *	Thr *	lie *	Lys •	Phe *	Giy •	lie *	Glu *	Thr *	Me:	Tyr *	Pro *	Ala •	Leu *	Giy *	Leu *	His *	Glu *	Phe *	Aia Ser	Giy *	Giu *	Leu •	Ser Thr	Thr +	Leu lie	Glu *	Ser •	Leu •	Met •
		_		915					930					945					960					975					990
Asn Met	Leu *	Tyr *	Gin *	Gin •	Met •	Giy •	Lys Giu	Pro Thr	Ala *	Pro •	Tyr *	Met *	Va! •	Asn Ile	Leu *	Glu *	Asn *	Ser *	lie Vai	Gin *	Ash *	Lys *	Phe *	Ser *	Ala •	Giy •	Ser •	Tyr •	Pro *
																													1080
Leu *				1005					1020					1035					1050					1065					
	Leu *	Trp •	Ser •	1005 Tyr *	Ala *	Met *	Giy *	Vai *	1020 Giy	Vai *	Glu •	Leu •	Giu *	1035 Asn •	Ser *	Met •	Giy	Giy	1050 Leu	Asn Giy	Phe •	Giy	Arg •		Tyr •	Phe *	Asp *	Pro *	Aia •
	٠	•	٠	Tyr * 1095	٠	•	*	•	Giy * 1110	•	•	•	•	Asn * 1125	٠	•	•	•	Leu • 1140	Giy	•	٠	Arg *	Ser * 1155	•	•	Asp *	•	* 1170
Tyr *	* Phe	Trp * Arg	٠	Tyr •	Ala * Gin	Met * Glu	Giy * Met	Vai * Vai *	Giy *	Vai * Arg	Glu * Ser	Leu * Ala	Giu * Giy	Asn *	Ser * Vai	Met * Ser	Giy * Ser	•	Leu •	Giy	Phe * Ser Aia	Giy * Giu	Arg * Leu *	Ser *	Tyr * Ile	Phe * Thr	Asp * Ala Lys	•	•
Tyr *	٠	•	* Leu *	Tyr * 1095	٠	•	*	val	Giy * 1110	٠	•	•	* Gly *	Asn 1125 Lys 1215	٠	•	* Ser *	* Thr	Leu • 1140 Leu	Giy	• Ser	* Glu *	•	Ser * 1155	•	•	* Ala	•	* 1170 Asp
Tyr * Ala *	٠	•	* Leu *	Tyr * 1095 Gly *	٠	•	*	val	Giy * 1110 Arg *	* Arg *	* Ser *	* Ala *	* Gly *	Asn * 1125 Lys *	٠	•	* Ser *	* Thr	Leu * 1140 Leu *	Giy	• Ser	* Glu *	•	Ser * 1155 Gly * 1245	•	•	* Ala	•	* 1170 Asp Glu 1260
*	* Phe * Arg	* Arg *	* Leu * Vai *	Tyr * 1095 Gly * 1185	* Gin *	* Glu *	* Met *	* Val * Met	Giy * 1110 Arg * 1200 His	* Arg * Thr	* Ser *	* Ala *	* Gly *	Asn * 1125 Lys * 1215 Lys	* Vai *	* Ser * Ser	* Ser * Arg	* Thr Ala Ala	Leu * 1140 Leu * 1230 Vai	Giy Ala * Giy	* Ser Ala	* Giu * Arg	* Leu *	Ser * 1155 Gly * 1245 Ala	lle * Gin	* Thr * Val	* Ala Lys Ser	* Glu	* 1170 Asp Glu 1260
* Ala * Gin	* Phe * Arg Gin Giy	* Arg * Leu *	* Leu * Vai * Gin	Tyr * 1095 Gly * 1185 Ser * 1275	* * Glu	* Glu * Ile	* Met * Ala *	* Val * Met Ser Leu	Giy * 1110 Arg * 1200 His Lys 1290	* Arg * Thr * Arg	* Ser * Thr * Leu	* Ala * Giu	Giy * Asp * Giy	Asn * 1125 Lys * 1215 Lys Arg 1305 Lys	Vai * lie Thr	* Ser fle Asp	* Ser * Arg	* Ala Ala *	Leu * 1140 Leu * 1230 Val Thr	Giy Ala * Giy *	* Aia Pro *	* Giu * Arg Lys	+ Leu + Gin + Arg	Ser * 1155 Gly * 1245 Ala Ser	tile t Gin t Giu	* Thr * Val Ile	* Ala Lys Ser Thr	* Glu * Phe * Glu	* 1170 Asp Glu 1260 Leu * 1350
* Ala * Gin	* Phe * Arg Gin Giy	* Arg * Leu *	* Leu * Vai *	Tyr * 1095 Gly * 1185 Ser * 1275 Ser	* Gin * Giu * Giu	* Glu * Ile * Asn	* Met * Ala *	* Val * Met Ser Leu	Giy * 1110 Arg * 1200 His Lys 1290 Pro	* Arg * Thr * Arg	* Ser * Thr * Leu	Ala * Giu *	* Giy * Asp * Giy	Asn * 1125 Lys * 1215 Lys Arg 1305 Lys	• Val • Ile Thr Glu	* Ser fle Asp	* Ser * Arg *	* Ala Ala *	Leu * 1140 Leu * 1230 Val Thr 1320 Val	Giy Ala * Giy *	* Aia Pro *	* Giu * Arg Lys Ser	+ Leu + Gin + Arg	Ser * 1155 Gly * 1245 Ala Ser 1335 Gly	tile t Gin t Giu	* Thr * Vai ile Ala	* Ala Lys Ser Thr Arg	* Glu * Phe * Glu	* 1170 Asp Glu 1260 Leu * 1350 Ser
* Ala * Gin His Tyr	* Phe * Arg Gin Giy Ser Arg	* Arg * Leu *	* Leu * Val * Gin Arg Thr	Tyr * 1095 Gly * 1185 Ser * 1275 Ser * 1365	* Gin * Giu * Giu *	* Glu * Ile * Asn Val Ser	* Met * Ala * Glu Ala	* Val * Met Ser Leu Asn Ala	Giy * 1110 Arg * 1200 His Lys 1290 Pro Gin 1380 Ser	* Arg * Thr * Arg	* Ser * Thr * Leu Pro	* Ala * Giu * Giy Pro	* Gly * Asp * Gly Thr	Asn * 1125 Lys * 1215 Lys Arg 1305 Lys IIe 1395	• Val • Ile Thr Glu	* Ser Ile Asp Lys	* Ser * Arg * Arg	* Ala Ala * Arg Ser	Leu * 1140 Leu * 1230 Val Thr 1320 Val Glu	Giy Ala * Giy * Lys Asn	* Aia Pro * Gin	* Giu * Arg Lys Ser	* Gin * Arg Gly	Ser * 1155 Gly * 1245 Ala Ser 1335 Gly Asp	t Ile t Gin t Giu Lys	* Thr * Vai ile Ala	* Ala Lys Ser Thr Arg	* Glu * Phe * Glu Ile	* 1170 Asp Glu 1260 Leu * 1350 Ser His 1440 Glu
* Ala * Gin His Tyr	* Phe * Arg Gin Giy Ser Arg	* Arg * Leu * Asp Glu Glu	* Leu * Val * Gin Arg Thr	Tyr * 1095 Gly * 1185 Ser * 1275 Ser * 1365 Gly	* Gin * Giu * Giu *	* Glu * Ile * Asn Val Ser	* Met * Ala * Glu Ala	* Val * Met Ser Leu Asn Ala	Giy * 1110 Arg * 1200 His Lys 1290 Pro Gin 1380 Ser	* Arg * Thr * Arg Gin Asp	* Ser * Thr * Leu Pro	* Ala * Giu Pro Arg	* Gly * Asp * Gly Thr	Asn * 1125 Lys * 1215 Lys Arg 1305 Lys Ile 1395 Ala	* Val Ile Thr Glu Asn His	* Ser Ile Asp Lys	* Ser * Arg * Arg * Pro	* Thr Ala Ala * Arg Ser Thr	Leu * 1140 Leu * 1230 Vai Thr 1320 Vai Glu 1410 Gly	Giy Ala * Giy * Lys Asn Thr	* Aia Pro * Gin *	* Giu * Arg Lys Ser Gly Leu	* Gin * Arg Gly	Ser * 1155 Gly * 1245 Ala Ser 1335 Gly Asp 1425 Ile	lle * Gin * Glu Lys	* Thr * Val Ile Ala Tyr	* Ala Lys Ser Thr Arg Pro Ala	* Glu * Phe * Glu Ile	* 1170 Asp Glu 1260 Leu * 1350 Ser His 1440 Glu
* Ala * Gin His Tyr	* Phe * Arg Gin Giy Ser Arg Ser Ser	* Arg * Leu * Asp Glu Glu	* Leu * Vai * Gin Arg Thr Glu	Tyr * 1095 Gly * 1185 Ser * 1365 Gly Arg 1455	* Gin * Giu * Pro Leu Gin	* Glu * Ile * Asn Val Ser Leu	* Met * Ala * Glu Ala	* Val * Met Ser Leu Asn Ala Tyr	Giy * 1110 Arg * 1200 His Lys 1290 Pro Gin 1380 Ser Thr	* Arg * Thr * Arg Gin Asp Pro Ser	* Ser * Thr * Leu Pro Ala Asp	* Ala * Giu * Giy Pro Arg Vai	* Gly * Gly Thr Ala Asn Pro	Asn 1125 Lys 1215 Lys Arg 1305 Lys IIe 1395 Ala Ser 1485 Leu	* Val Ile Thr Glu Asn His Ser Leu	* Ser Ile Asp Lys Leu Glu Ser	* Ser * Arg * Arg * Pro Arg Cys	* Thr Ala Ala * Arg Ser Thr Ser Lys	Leu * 1140 Leu * 1230 Val Thr 1320 Val Glu \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	Gly Ala * Gly * Lys Asn Thr Ser Trp	* Ser Aia Pro * Gin * Pro Arg Gin	* Glu * Arg Lys Ser Gly Leu Tyr Glu	* Leu * Gin * Arg Gly Asp	Ser * 1155 Gly * 1245 Ala Ser 1335 Gly Asp 1425 Ile Thr 1515 Arg	• Gin • Glu Lys Gin	* Thr * Val Ile Ala Tyr Thr Ile Asn	 Ala Lys Ser Thr Arg Pro Ala Val Lys 	* Glu * Phe * Glu Ile Ser Gln	* 1170 Asp Glu 1260 Leu * 1350 Ser His 1440 Glu Asp Glu 1530 Glu Glu 1530 Glu
+ Ala + Gin His Tyr Phe Ser	* Phe * Arg Gin Giy Ser Arg Ser Ser	 Arg Leu Asp Glu Asp Glu Asp Glin 	* Leu * Vai * Gin Arg Thr Glu Asp	Tyr * 1095 Gly * 1185 Ser * 1275 Ser * 1365 Gly Arg 1455 Pro	* Gin * Giu * Pro Leu Gin	* Glu * Ile * Asn Val Ser Leu Asp	* Met * Ala * Glu Ala Gly Ser	* Val * Met Ser Leu Asn Ala Tyr	Giy * 1110 Arg * 1200 His Lys 1290 Pro Gin 1380 Ser Thr 1470 Arg	* Arg * Thr * Arg Gin Asp Pro Ser	* Ser * Thr * Leu Pro Ala Asp	* Ala * Giu * Giy Pro Arg Val Glu	* Gly * Gly Thr Ala Asn Pro	Asn 1125 Lys 1215 Lys Arg 1305 Lys IIe 1395 Ala Ser 1485 Leu	* Val Ile Thr Glu Asn His Ser Leu	* Ser Ile Asp Lys Leu Glu Ser	* Ser * Arg * Arg * Pro Arg Cys	* Thr Ala Ala * Arg Ser Thr Ser Lys	Leu 1140 Leu 1230 Val 1320 Val Glu 1410 Gly * 1500 Pro	Gly Ala * Gly * Lys Asn Thr Ser Trp	* Ser Aia Pro * Gin * Pro Arg Gin	* Glu * Arg Lys Ser Gly Leu Tyr Glu	* Leu * Gin * Arg Gly * Ser	Ser * 1155 Gly * 1245 Ala Ser 1335 Gly Asp 1425 Ile Thr 1515 Arg	* Ile * Gin * Giu Lys	* Thr * Val Ile Ala Tyr Thr Ile Asn	 Ala Lys Ser Thr Arg Pro Ala Val Lys 	* Glu * Phe * Glu Ile Ser Gln Ala	* 1170 Asp Glu 1260 Leu * 1350 Ser His 1440 Glu Asp Glu 1530 Glu Glu 1530 Glu
Ala Ala Gin His Tyr Phe Ser Asp Thr	* Phe * Arg Gin Giy Ser Arg Ser Giy	Arg Arg Leu Asp Glu Glu Asp Gln Asn Thr	+ Leu * Vai * Gln Arg Glu Asp *	Tyr * 1095 Gly * 1185 Ser * 1275 Ser * 1365 Gly Arg 1455 Pro Asp 1545	* Giu * Giu * Pro Leu Gin Asp Gin	* Glu * Ile * Asn Val Ser Leu Asp Arg Cys	* Met * Ala * Glu Ala Gly Ser Lys Thr	* Val * Met Ser Leu Asn Ala Tyr Arg Ser Met	Giy * 1110 Arg * 1200 His Lys 1290 Pro Gin 1380 Ser Thr 1470 Arg Met	* Arg Thr * Arg Gin Asp Pro Ser Giu Giu	* Ser * Thr * Leu Pro Ala Asp Ala *	* Ala * Giu Pro Arg Vai Glu Ile Phe	* Gly * Gly Thr Ala Asn Pro Ala X	Asn 1125 Lys 1215 Lys Arg 1305 Lys IIe 1395 Ala Ser 1485 Leu	* Val Ile Thr Glu Asn His Ser Leu	* Ser Ile Asp Lys Leu Glu Ser	* Ser * Arg * Arg * Pro Arg Cys	* Thr Ala Ala * Arg Ser Thr Ser Lys	Leu 1140 Leu 1230 Val 1320 Val Glu 1410 Gly * 1500 Pro	Gly Ala * Gly * Lys Asn Thr Ser Trp	* Ser Aia Pro * Gin * Pro Arg Gin	* Glu * Arg Lys Ser Gly Leu Tyr	* Leu * Gin * Arg Gly * Ser	Ser * 1155 Gly * 1245 Ala Ser 1335 Gly Asp 1425 Ile Thr 1515 Arg	* Ile * Gin * Giu Lys	* Thr * Val Ile Ala Tyr Thr Ile Asn	 Ala Lys Ser Thr Arg Pro Ala Val Lys 	* Glu * Phe * Glu Ile Ser Gln Ala	* 1170 Asp Glu 1260 Leu * 1350 Ser His 1440 Glu Asp Glu 1530 Glu Glu 1530 Glu

FIG. 6. Predicted amino acid sequences of MV and CDV nucleocapsid protein. Asterisks represent amino acid identity; \times , termination codon; nd, not determined.

amino acid levels (Fig. 5 and 6). Thus, it was concluded that CDV 364 and related clones represent a class of cDNA clones specific for the nucleocapsid gene of CDV.

DISCUSSION

In the present report, we have identified cDNA clones specific for the nucleocapsid of CDV. One particular clone (364) has been studied in detail. Northern analysis of CDV and MV mRNA with CDV 364 as probe indicated that, under decreased stringency, an mRNA of ca. 1,850 nucleotides was detected in both mRNA preparations. The size of this mRNA was consistent with the mRNA species detected by a CDV nucleocapsid specific clone reported previously (3) and with the mRNA detected by a measles nucleocapsid clone, MV CL-15 (11). An additional mRNA species of ca. 3,500 bases was detected in both mRNA preparations. This most likely represents a readthrough dicistronic mRNA of the type previously described for negative-strand RNA viruses (13, 27). Heteroduplex mapping between MV CL-15 and CDV 364 indicated sequence homology in the central region of the CDV-MV hybrid molecules, with an average duplex length of 681 \pm 48 nucleotides. Clone 364 has been employed in hybrid selection studies not shown here. Subsequent in vitro translation of the selected CDV mRNA resulted in the synthesis of polypeptides ranging from 60,000 to 20,000 in molecular weight. Only the largest polypeptide comigrated with the authentic nucleocapsid protein of CDV. The lowermolecular-weight products are believed to be nucleocapsidrelated peptides, possibly a result of premature termination in the in vitro translation system. A similar phenomenon was observed with hybrid-selected mRNA encoding the nucleocapsid protein of MV (11, 19). The most compelling data for the nucleocapsid specificity of CDV 364 and related clones stem from the striking homology with the MV sequence at the nucleotide level and especially at the amino acid level (Fig. 5 and 6).

Alignment of these sequences was done at their respective termination codons at the end of each single open reading frame of the deduced messages. The strongest homology began at nucleotide 501 and extended to nucleotide 1215. This region contains 715 nucleotides, of which 77% of the measles and CDV sequences are identical. Both the central location and the number of nucleotide sequencing, are in excellent agreement with the location and length of the heteroduplexes observed.

A region of moderate homology was observed at the 5' end of the deduced mRNA sequences. This region, which encompasses nucleotides 28 through 500 of the MV coding sequence, is 59% homologous with that of the sequence derived from CDV 364. Unfortunately, no CDV clone was identified that would allow the analysis of the most 5' sequences. In contrast to the two regions of homologous sequence identified within the first 1,200 nucleotides, little or no homology could be detected in the last 400 nucleotides toward the 3' ends of these deduced messages. It should be emphasized that the sequences in the latter regions were derived from three independently isolated clones of CDV and from two clones, one message derived and one genomic derived, of measles nucleocapsid. Thus, the regions of nonhomology represent the best analyzed with respect to nucleotide sequence accuracy.

Measles and CDV antisera very strongly cross-react with respect to the nucleocapsid protein (12, 15, 17). The deduced amino acid sequences (Fig. 6) of the available CDV and MV nucleocapsid proteins suggest that the cross-reactivity of such antisera would likely occur within the regions of moderate and high homology where 66 and 88% of the respective amino acid sequences are identical. These percentages are somewhat higher than those observed at the nucleotide level. Many of the nucleotide changes occur at the third position of the triplet codon and often encode the same amino acid. In many instances in which the nucleotide change encodes a different amino acid, the properties of the substituted amino acid are identical, i.e., non-polar uncharged, polar uncharged, etc. (Fig. 6).

In contrast, the last 107 amino acids of the deduced sequences show only chance homology. The sequence predicts that unique antibody populations reacting exclusively with either MV or CDV nucleocapsid should exist. Antibodies to synthetic oligopeptides constructed to these clearly divergent regions will be powerful tools for assessing the importance of the divergence in terms of protein-protein or protein-nucleic acid interactions, or both.

Recently, the complete nucleotide sequence of the nucleocapsid gene of a third paramyxovirus, Sendai virus, has been reported (24). A direct comparison of the coding region of this sequence with MV and CDV at the amino acid level was performed by aligning the sequences at the putative initiator methionine of Sendai and MV nucleocapsid proteins. This comparison resulted in the identification of two regions of precise identity. The first contained six amino acids, Ala-Gly-Leu-Ala-Ser-Phe (nucleotides 790 to 807), and the second contained eight amino acids, Leu-Trp-Ser-Tyr-Ala-Met-Gly-Val (nucleotides 994 to 1017). It should be stressed that these regions, although small, occur precisely in the same location from the first methionine used to align the sequences. Whether these conserved sequences serve some functional role in RNA binding is currently under investigation.

ACKNOWLEDGMENTS

S.R. and W.J.B. thank R. A. Lazzarini for his support and encouragement.

LITERATURE CITED

- Appel, M. J. G., E. P. J. Gibbs, S. J. Martin, V. Ter Meulen, B. K. Rima, J. R. Stephenson, and M. P. Taylor. 1984. Morbillivirus diseases of animals and man, p. 235–297. *In* E. Kurstak and C. Kurstak (ed.), Comparative diagnosis of viral diseases, vol. 4. Academic Press, Inc., New York.
- 2. Aviv, H., and P. Leder. 1972. Purification of biologically active globin messenger RNA by chromotography on oligothymidylic acid-cellulose. Proc. Natl. Acad. Sci. U.S.A. 65:1408–1412.
- Barrett, T., and B. W. J. Mahy. 1984. Molecular cloning of the nucleoprotein gene of canine distemper virus. J. Gen. Virol. 65:549-557.
- 4. Bellini, W. J., G. Englund, C. D. Richardson, R. N. Hogan, S. Rozenblatt, C. A. Meyers, and R. A. Lazzarini. 1984. Positive identification and molecular cloning of the phosphoprotein of measles virus, p. 359–364. *In* R. Compans and D. Bishop (ed.), The molecular biology of negative strand viruses. Academic Press, Inc., San Francisco.
- Bellini, W. J., G. Englund, C. D. Richardson, and S. Rozenblatt. 1984. Positive identification of a measles virus cDNA clone encoding a region of the phosphoprotein. J. Virol. 50:939–942.
- Billeter, M. A., K. Baczko, A. Schmid, and V. Ter Meulen. 1984. Cloning of DNA corresponding to four different measles virus genomic regions. Virology 132:147–159.
- 7. Bratosin, S., M. Horowitz, O. Lamb, and Y. Aloni. 1978. Electron microscopic evidence for splicing of SV40 late mRNA. Cell 13:783-790.
- Connoly, J. H., I. V. Allen, L. J. Hurwitz, and J. H. D. Miller. 1967. Measles-virus antibody and antigen in subacute sclerosing panencephalitis. Lancet ii:542–544.
- Cook, S. D., P. C. Dowling, and W. C. Russel. 1979. Neutralizing antibodies to canine distemper and measles virus in multiple sclerosis. J. Neurol. Sci. 41:61–70.
- Derman, E., K. Krauter, L. Walling, C. Weinberger, M. Ray, and J. E. Darnell, Jr. 1981. Transcriptional control in the production of liver-specific mRNAs. Cell 23:731-739.
- Gorecki, M., and S. Rozenblatt. 1980. Cloning of DNA complementary to the measles virus mRNA encoding nucleocapsid protein. Proc. Natl. Acad. Sci. U.S.A. 77:3686-3690.
- 12. Hall, W. W., R. A. Lamb, and P. W. Choppin. 1980. The polypeptides of canine distemper virus synthesis in infected cells and relatedness to the polypeptides of other morbilli-viruses. Virology 100:433-449.
- Herman, R. C., M. Schubert, J. D. Keene, and R. A. Lazzarini. 1980. Polycistronic vesicular stomatitis virus RNA transcripts. Proc. Natl. Acad. Sci. U.S.A. 77:4662-4665.
- 14. Horta-Barbosa, L., D. A. Fuccillo, and J. L. Sever. 1967. Subacute sclerosing panencephalitis: isolation of measles virus from a brain biopsy. Nature (London) 22:974.
- Imagawa, D. T., P. Goret, and J. M. Adams. 1960. Immunological relationships of measles, distemper and rinderpest viruses. Pathology 46:1119-1123.
- Maxam, A. M., and W. Gilbert. 1980. Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol. 65:499-560.
- 17. Örvell, C., and E. Norrby. 1980. Immunological relationships between homologous structural polypeptides of measles and canine distemper virus. J. Gen. Virol. 50:231-245.
- 18. Payne, F. E., J. V. Baublis, and H. H. Itabashi. 1969. Isolation

of measles virus from a patient with subacute sclerosing panencephalitis. N. Engl. J. Med. 284:585-589.

- Rozenblatt, S., C. Gesang, V. Lavie, and F. S. Neumann. 1982. Cloning and characterization of DNA complementary to the measles virus mRNA encoding hemagglutinin and matrix protein. J. Virol. 42:790-797.
- Rozenblatt, S., M. Gorecki, H. Shure, and C. L. Prives. 1979. Characterization of measles virus-specific proteins synthesized in vivo and in vitro from acutely and persistently infected cells. J. Virol. 29:1099–1106.
- Rustigian, R. 1966. Persistent infection of cells in culture by measles virus. I. Development and characteristics of HeLa sublines persistently infected with complete virus. J. Bacteriol. 92:1792-1804.
- 22. Sanger, F., A. R. Coulson, B. G. Barrel, A. J. H. Smith, and B. A. Roe. 1980. Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing. J. Mol. Biol. 143:161-178.
- 23. Shapshak, P., M. C. Graves, and D. T. Imagawa. 1982. Poly-

peptides of canine distemper virus strains from dogs with chronic neurological diseases. Virology **122:**158–170.

- 24. Shioda, T., Y. Hidaka, T. Kanda, H. Shibuta, A. Nomoto, and K. Iwasaki. 1983. Sequence of 3,687 nucleotides from the 3' end of Sendai virus genome RNA and the predicted amino acid sequences of viral NP, P and C proteins. Nucleic Acid Res. 11:7317-7330.
- Stephenson, J. R., and V. Ter Meulen. 1979. Antigenic relationship between measles and canine distemper viruses: comparison of immune response in animal and humans to individual virusspecific polypeptides. Proc. Natl. Acad. Sci. U.S.A. 76: 6604-6605.
- 26. Wild, T. F., and P. Girandon. 1982. Synthesis of a unique polypeptide in measles virus-infected BGM cells. J. Gen. Virol. 63:247-250.
- Wilde, A., and T. Morrison. 1984. Structural and functional characterization of Newcastle disease virus polycistronic RNA species. J. Virol. 51:71-76.